ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1308

Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study

Diala Alawneh1, Moustafa Younis2, Romesa Hassan1, Bashar Alzghoul2, Shiva Arami1, Tricha Shivas3, Mary McGowan3, Khaldoon Alawneh4, Christian Ascoli1 and Nadera Sweiss1, 1University of Illinois at Chicago, Chicago, IL, 2University of Florida, Gainesville, FL, 3Foundation for Sarcoidosis Research, Chicago, IL, 4Jordan University of Science and Technology, Irbid, Jordan

Meeting: ACR Convergence 2022

Keywords: Miscellaneous Rheumatic and Inflammatory Diseases, osteoporosis, population studies, registry

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with sarcoidosis are at an increased risk of developing osteoporosis due to the active inflammatory state and chronic corticosteroid use. Proper dosing of vitamin D and calcium supplements is challenging given the risk of hypercalcemia. There is no consensus regarding the optimal strategies in management of osteoporosis in sarcoidosis patients. We sought to evaluate the prevalence, risk factors and therapeutic practices in patients with osteoporosis in the United States based on a national registry questionnaire.

Methods: We conducted a retrospective study based on a national registry investigating 3,835 respondents to the Foundation for Sarcoidosis Research – Sarcoidosis Advanced Registry for Cures Questionnaire (FSR-SARC). The registry includes patient surveys completed between June 2014 and August 2019. Summary and univariate analyses were performed.

Results: A total of 516 (13.5%) patients were identified to have osteoporosis. Among these, the mean age was 47 (± 13) years; 445 (86%) were female, 398 (77%) Caucasian and 96 (19%) African American. A diagnosis of osteoporosis was made after sarcoidosis diagnosis in 214/516 patients (42%). Patients with osteoporosis were significantly older than those without osteoporosis {47 (±13) vs 44 (±12); p< 0.0001}, however there was no significant difference in prevalence with regards to sex (p=0.333) Patients with osteoporosis had the following associated disorders: vitamin D deficiency (61%), Cushing’s Syndrome (6%), hyperparathyroidism (0.6%), hypothyroidism (25%), hyperthyroidism (6%), low testosterone levels (10%), diabetes (21%), hypercalciuria (3%) and obesity (37%). Patients with osteoporosis had a significantly higher proportion of vitamin D deficiency compared to patients without (61% vs 33%, OR= 3.1, 95% CI 2.6-3.8; p< 0.0001). A total of 426 (97%) received the following therapies during the course of their disease: 396 (77%) steroids, 247 (67%) cytotoxic meds and 72 (24%) TNF inhibitor. Patients with osteoporosis were actively receiving treatment of their sarcoidosis with a variety of therapies as shown in Table 1. Patients with osteoporosis were more likely to have received systemic steroids (OR=2.8; 95% CI: 2.2-3.7; p< 0.0001), inhaled steroids (OR=1.6; 95% CI: 1.3-1.9; p< 0.0001), cytotoxic meds (OR= 1.54; 95% CI: 1.2-2.0; p< 0.0001) and TNF inhibitors (OR= 1.5; 95% CI: 1.2-2.0; p< 0.0001). A total of 124 (24%) received bisphosphonate therapy and 223 (43%) received vitamin D (D2, D3 or combined Ca-vitamin D) for treatment of osteoporosis.

Conclusion: A significant proportion of patients with sarcoidosis develop osteoporosis with no sex predilection, however older patients and Caucasian were more at risk. Concurrent vitamin D deficiency was significantly associated with osteoporosis in these patients. Patients with osteoporosis were more likely to be on systemic and/or inhaled steroids along with other immunosuppressants. Only a quarter of patients with osteoporosis received bisphosphonates.

Supporting image 1

Table 1: Treatments patients with osteoporosis were actively receiving for sarcoidosis


Disclosures: D. Alawneh, None; M. Younis, None; R. Hassan, None; B. Alzghoul, None; S. Arami, None; T. Shivas, None; M. McGowan, None; K. Alawneh, None; C. Ascoli, None; N. Sweiss, None.

To cite this abstract in AMA style:

Alawneh D, Younis M, Hassan R, Alzghoul B, Arami S, Shivas T, McGowan M, Alawneh K, Ascoli C, Sweiss N. Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/prevalence-and-therapeutic-practices-of-osteoporosis-in-sarcoidosis-in-the-united-states-a-nationwide-registry-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-and-therapeutic-practices-of-osteoporosis-in-sarcoidosis-in-the-united-states-a-nationwide-registry-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology